Fast Track designation adds regulatory momentum ahead of Phase 2 data readouts expected in 2H 2026. The designation, combined with existing Orphan Drug and Rare Pediatric Disease status, increases the probability of a streamlined approval pathway. Traders should watch for Phase 2 data catalysts in 2H 2026 as the next major value inflection point.
Price Chart
Executive Summary
Satellos Bioscience received FDA Fast Track designation for SAT-3247 in Duchenne muscular dystrophy, adding to existing Orphan Drug and Rare Pediatric Disease designations. The designation enables expedited development and review, including potential rolling review and Accelerated Approval eligibility. Phase 2 BASECAMP and TRAILHEAD studies are ongoing with additional data expected in 2H 2026.
Key Facts
- FDA granted Fast Track designation for SAT-3247 in Duchenne muscular dystrophy
- SAT-3247 now has Fast Track, Orphan Drug, and Rare Pediatric Disease designations
- Fast Track enables more frequent FDA interactions, rolling review, and potential Accelerated Approval and Priority Review
- Phase 2 BASECAMP (pediatric, placebo-controlled) and TRAILHEAD (adult, open-label) studies are ongoing
- Additional data expected in 2H 2026
Financial Impact
No financial figures disclosed. Fast Track designation is a regulatory milestone that may accelerate development timelines and reduce regulatory risk, but has no direct revenue impact.
Risk Factors
- Phase 2 data may fail to meet efficacy endpoints, negating regulatory advantages
- Clinical-stage biotech with no approved products or revenue — binary risk on trial outcomes
- Fast Track designation does not guarantee approval or change the fundamental risk profile of the drug candidate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004332 |
| Document: f6k_062926.htm | 0001171843-26-004332 |
| Document: 0001171843-26-004332-index-headers.html | 0001171843-26-004332 |
| Document: 0001171843-26-004332-index.html | 0001171843-26-004332 |
| Document: 0001171843-26-004332.txt | 0001171843-26-004332 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $6.70 | awaiting T+20 | — | $6.54 (−2.39%) |
Oct 5, 2026 21d ago | 6-K | $8.05 | awaiting T+20 | — | $6.54 (−18.76%) |
Sep 30, 2026 26d ago | 6-K | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 30, 2026 26d ago | Press Release | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 15, 2026 5w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.54 (−30.13%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.54 (−34.73%) |
Sep 1, 2026 7w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.54 (−27.97%) |
Aug 13, 2026 10w ago | 6-K | $9.61 $9.79 | ▲ +1.87% | ▲ +3.86% | $6.54 (−31.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers